for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ContraFect Corp

CFRX.OQ

Latest Trade

5.17USD

Change

-0.02(-0.39%)

Volume

65,370

Today's Range

5.05

 - 

5.22

52 Week Range

4.48

 - 

12.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.19
Open
5.19
Volume
65,370
3M AVG Volume
3.83
Today's High
5.22
Today's Low
5.05
52 Week High
12.40
52 Week Low
4.48
Shares Out (MIL)
27.81
Market Cap (MIL)
146.84
Forward P/E
-2.68
Dividend (Yield %)
--

Next Event

Q4 2020 ContraFect Corp Earnings Release

Latest Developments

More

Contrafect posts Q3 Earnings Per Share $0.12

Contrafect Announces Funding Agreement With The Cystic Fibrosis Foundation

ContraFect Reports Q2 Loss Per Share $0.88

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ContraFect Corp

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.

Industry

Biotechnology & Drugs

Contact Info

28 Wells Ave Ste 3

YONKERS, NY

10701-7045

United States

+1.914.2072300

https://www.contrafect.com/

Executive Leadership

Roger J. Pomerantz

Chairman of the Board, Chief Executive Officer

Michael Messinger

Chief Financial Officer

Cara M. Cassino

Executive Vice President - Research and Development, Chief Medical Officer

Nancy Dong

Vice President - Finance and Administration

Jane E. Ambler

Vice President - Clinical Microbiology

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.800

2018

-5.000

2019

-1.540

2020(E)

-1.615
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-98.86
Return on Equity (TTM)
-82.92

Latest News

Latest News

BRIEF-ContraFect Appoints Lishan Aklog To Board Of Directors

* CONTRAFECT ANNOUNCES APPOINTMENT OF LISHAN AKLOG, M.D. TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Cvi Investments Inc Reports 8.3% Passive Stake In Contrafect Corp As Of May 22

* CVI INVESTMENTS INC REPORTS 8.3% PASSIVE STAKE IN CONTRAFECT CORP AS OF MAY 22 - SEC FILING Source text - https://bit.ly/3ewO3fO Further company coverage:

BRIEF-ContraFect Corporation Announces Private Placement Of Common Stock And Warrants To Pfizer

* CONTRAFECT CORPORATION ANNOUNCES PRIVATE PLACEMENT OF COMMON STOCK AND WARRANTS TO PFIZER INC.

BRIEF-Contrafect Prices Approximately $52.5 Million Public Offering Of Common Stock And Warrants

* CONTRAFECT CORPORATION PRICES APPROXIMATELY $52.5 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-ContraFect Announces Proposed Public Offering Of Common Stock And Warrants

* CONTRAFECT CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Contrafect Reports Q1 Loss Per Share Of $0.49

* CONTRAFECT REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-ContraFect Posts Q4 Loss Per Share Of $1.11

* CONTRAFECT REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Contrafect Announces FDA's Breakthrough Therapy Designation To Exebacase

* CONTRAFECT ANNOUNCES U.S. FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO EXEBACASE FOR THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) BACTEREMIA, INCLUDING RIGHT-SIDED ENDOCARDITIS Source text for Eikon: Further company coverage:

BRIEF-ContraFect Announces Q1 Loss Per Share $0.26

* CONTRAFECT - AS OF MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $39.9 MILLION, COMPARED TO $46.9 MILLION AS OF DECEMBER 31, 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up